Therapeutic proteins: A to Z

Protein and Peptide Letters

Volumn 20, Issue 12, 2013, Pages 1365-1372

  Özgür, Aykut ^a   Tutar, Yusuf ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Insulin and erythropoietin; Interferons; Monoclonal antibodies; Recombinant DNA technologies; Therapeutic proteins

Indexed keywords

ERYTHROPOIETIN; INSULIN; INTERFERON; MONOCLONAL ANTIBODY; PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RECOMBINANT DNA TECHNOLOGY; ANIMAL; CELL LINE; CHO CELL LINE; CRICETULUS; ESCHERICHIA COLI; MOUSE; PROTEIN ENGINEERING; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CHO CELLS; CRICETULUS; ERYTHROPOIETIN; ESCHERICHIA COLI; HUMANS; INSULIN; INTERFERONS; MICE; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 84887897897     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986652012131112125148     Document Type: Article

References (83)

1. Pavlov, A.K.; Belsey, M.J. The therapeutic antibodies market to2008. Eur. J. Pharm. Biopharm., 2005, 59, 389-96.
2. Han, W.; Li, X.; Fu, X. The macro domain protein family: Structure, functions, and their potential therapeutic implications. Mutat. Res., 2011, 727, 86-103.
3. Löfblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Stahl, S.; Frejd, F.Y. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett., 2010, 584, 2670-80.
4. Tutar, Y.; Tutar, L. Heat shock proteins: an overview. Curr. Pharm. Biotechnol., 2010, 11, 216-22.
5. Demain, A.L.; Vaishnav, P. Production of recombinant proteins bymicrobes and higher organisms. Biotechnol. Adv., 2009, 27, 297-306.
6. Gualandi-Signorini, A.M.; Giorgi, G. Inulin formulations -a review. Eur. Rev. Med. Pharmacol. Sci., 2001, 5, 73-83.
7. Schellekens, H. Immunogenicity of therapeutic proteins: Clinicalimplications and future prospects. Clin. Ther., 2002, 24, 1720-40.
8. Nayak, A.K. Advances in therapeutic protein production and delivery. Int. J. Pharm. Pharm. Sci., 2010, 2, 1-5.
9. Roy, N.; Agarwal, S. Therapeutic protein production -an overview. Business Briefing: Future Drug Discovery, 2003, 79-82.
10. Krippendorff, B.F.; Kuester K.; Kloft, C.; Huisinga, W. Nonlinearpharmacokinetics of therapeutic proteins resulting from receptormediated endocytosis. J. Pharmacokinet. Pharmacodyn., 2009, 36, 239-60.
11. Andersen, D.C.; Krummen, L. Recombinant protein expression for the rapeutic applications. Curr. Opin. Biotechnol., 2002, 13, 117-23.
12. Swiech, K.; Picanço-Castro, V.; Covas, D.T. Human cells: newplatform for recombinant therapeutic protein production. ProteinExpr. Purif., 2012, 84, 147-53.
13. Kamionka, M. Engineering of therapeutic proteins production in Escherichia coli. Curr. Opin. Biotechnol., 2011, 12, 268-74.
14. Çelik, E.; Çali{dotless}k, P. Production of recombinant proteins by yeastcells. Biotechnol. Adv., 2012, 30, 1108-18.
15. Zhu, J. Mammalian cell protein expression for biopharmaceuticalproduction. Biotechnol. Adv., 2012, 30, 1158-70.
16. Mahmood, I.; Green, M.D. Pharmacokinetic and pharmacodynamicconsiderations in the development of therapeutic proteins. Clin. Pharmacokinet., 2005, 44, 331-47.
17. Li, H.; d'Anjou, M. Pharmacological significance of glycosylationin therapeutic proteins. Curr. Opin. Biotechnol., 2009, 20, 678-84.
18. Sola, R.J.; Griebenow, K. Glycosylation of therapeutic proteins: aneffective strategy to optimize efficacy. BioDrugs, 2010, 24, 9-21.
19. Wacker, C.; Berger, C.N.; Girard, P.; Meier, R. Glycosylationprofiles of therapeutic antibody pharmaceuticals. Eur. J. Pharm. Biopharm., 2011, 79, 503-7.
20. Swartz, J.R. Advances in Escherichia coli production of therapeuticproteins. Curr. Pharm. Biotechnol., 2001, 12, 195-201.
21. Zhou, J.; Zhang, H.; Liu, X.; Wang, P.G.; Qi, Q. Influence of Nglycosylationon Saccharomyces cerevisiae morphology: a golgiglycosylation mutant shows cell division defects. Curr. Microbiol., 2007, 55, 198-204.
22. Elvin, J.G.; Couston, R.G.; Van Der Walle, C.F. Therapeutic antibodies:market considerations, disease, targets and bioprocessing. Int. J. Pharm., 2013, 440, 83-98.
23. Andersen, D.C.; Reily, D.E. Production technologies for monoclonalantibodies and their fragments. Curr. Opin. Biotechnol., 2004, 15, 456-62.
24. Matasci, M.; Hacker, D.L.; Baldi, L.; Wurm, F.M. Recombinanttherapeutic protein production in cultivated mammalian cells: currentstatus and future prospects. Drug Discov. Today, 2008, 5, 37-42.
25. Cacciatore, J.J.; Chasin, L.A.; Leonard, E.F. Gene amplification and vector engineering to achieve rapid and high-level therapeuticprotein production using the Dhfr-based CHO cell selection system. Biotechnol. Adv., 2010, 28, 673-81.
26. Larrick, J.W.; Thomas, D.W. Producing proteins in transgenicplants and animals. Curr. Pharm. Biotechnol., 2001, 12, 411-8.
27. Lillico, S.G.; McGrew, M.L.; Sherman, A.; Sang, H.M. Transgenicchickens as bioreactors for protein-based drugs. Drug Discov. Today, 2005, 10, 192-6.
28. Giddings, G. Transgenic plants as protein factories. Curr. Pharm. Biotechnol., 2001, 12, 450-4.
29. Gomord, V.; Faye, L. Posttranslational modification of therapeuticproteins in plants. Curr. Opin. Plant Biol., 2004, 7, 171-81.
30. Mahmood, I. Methods to determine pharmacokinetic profiles oftherapeutic proteins. Drug Discov. Today, 2009, 5, 65-9.
31. Bauman, A. Early development of therapeutic biologics -Pharmacokinetics. Curr. Drug Metab., 2006, 7, 15-21.
32. Lin, J.H.; Lu, A.Y.H. Role of pharmacokinetics and metabolism indrug discovery and development. Pharmacol. Rev., 1997, 49, 403-49.
33. Arhewoh, I.M.; Ahonkhai, E.I.; Okhamafe, A.O. Optimising oralsystems for the delivery of therapeutic proteins and peptides. Afr. J. Biotechnol., 2005, 4, 1591-7.
34. Mackay, M.; Philips, J.; Hastewell, J. Peptide drug delivery: Colonic and rectal absorption. Adv. Drug Deliv. Rev., 1997, 28, 253-73.
35. Chilistone, S.; Hardman, J. Factors affecting drug absorption anddistribution. Intensive Care. Med., 2008, 9, 167-71.
36. Vugmeyster, Y.; Xu, X.; Theil, F.P.; Khawli, L.A.; Leach, M.W. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J. Biol. Chem., 2012, 3, 73-92.
37. Arakawa, T.; Philo, J.S.; Ejima, D.; Tsumoto, K.; Arisaka, F. Aggregationanalysis of therapeutic proteins, part 1. BioProcess Int., 2006, 4, 42-3.
38. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm., 2005, 289, 1-30.
39. Tutar, Y.; Özgür, A.; Tutar, L. Role of protein aggregation in neurodegenerativediseases. InTech Publ., 2013, ISBN: 980-953-307-722-7.
40. Philo, J.S.; Arakawa, T. Mechanisms of protein aggregation. Curr. Pharm. Biotechnol., 2009, 10, 348-51.
41. Bondos, S.E.; Bicknell, A. Detection and prevention of proteinaggregation before, during, and after purification. Anal. Biochem., 2003, 316, 223-31.
42. Morris, A.M.; Watzky, M.A.; Finke, R.G. Protein aggregationkinetics, mechanism, and curve-fitting: A review of the literature. Biochim. Biophy. Acta., 2009, 1794, 375-97
43. Chennamsetty, N.; Voynov, V.; Kayser, V.; Helk, B.; Trout, B.L. Design of therapeutic proteins with enhanced srability. PNAS, 2009, 106, 11937-42.
44. Wang, W. Protein aggregation and its inhibition biopharmaceutics. Int. J. Pharm., 2005, 289, 1-30.
45. Lee, C.; Yu, M.H. Protein folding and diseases. Int. J. Biochem. Mol. Biol., 2005, 38, 275-80.
46. Scalley, M.L.; Baker, D. Protein folding kinetics exhibit an arrheniustemperature dependence when corrected for the temperaturedependence of protein stability. PNAS, 1997, 94, 10636-40.
47. Malik, R.; Roy, I. Probing the mechanism of insulin aggregationduring agitation. Int. J. Pharm., 2011, 413, 73-80.
48. Fridman, W.H. Principles of the therapeutic use of monoclonalantibodies in oncology. C. R. Biol., 2006, 329, 255-9.
49. El Bakri, A.; Nelson, P.N.; Abu Odeh, R.O. The state of antibodytherapy. Hum. Immunol., 2010, 71, 1243-50.
50. Borrebaeck C.A.K.; Carlsson, R. Human therapeutic antibodies. Curr. Opin. Pharmacol., 2001, 1, 404-8.
51. Binyamin, L.; Borghaei, H.; Weiner, L.M. Cancer theraphy withengineered monoclonal antibodies. Update Cancer Ther., 2006, 1, 147-57.
52. Funaro, A.; Horenstein, A.L.; Santoro, P.; Cinti, C.; Gregorini, A.; Malavasi, F. Monoclonal antibodies and therapy of human cancers. Biotechnol. Adv., 2000, 18, 385-401.
53. Tabrizi, M.A.; Tseng, C.M.L.; Roskos, L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today, 2006, 11, 81-7.
54. Sanchez-Martin, D.; Sanz, L.; Alvarez-Vallina, L. Engineeringhuman cells for in vivo secretion of antibody and non-antibodytherapeutic proteins. Curr. Opin. Biol., 2011, 22, 1-7.
55. Swann, P.G.; Tolnay, M.; Muthukkumar, S.; Shapiro, M.A.; Rellehan, B.L.; Clouse, K.A. Considerations for the development oftherapeutic monoclonal antibodies. Curr. Opin. Immunol., 2008, 20, 493-9.
56. Presta, L.G. Selection, design, and engineering of therapeutic antibodies. American Academy of Allergy, Asthma and Immunology, 2005, 116, 731-6.
57. Moreno, M.; Mol, B.M.; Mensdorff-Pouilly, S.V.; Verheijen, R.H.M.; Blomberg, B.M.E.; Eertwegh A.J.M.; Schepera, R.J.; Bontkes, H.J. Toll-like receptor agonists and invariant natural killerT-cells enhance antibody-dependent cell-mediated cytotoxicity(ADCC). Cancer Lett., 2008, 272, 70-6.
58. Bogdan, C.; Mattner, J.; Scleicher, U. The role of type I interferonsin non-viral infections. Immunol. Rev., 2004, 202, 33-48.
59. Friedman, R.M. Clinical uses of interferons. Br. J. Clin. Pharmacol., 2007, 65, 158-62.
60. Meager, A. Biological assays for interferons. J. Immunol. Methods., 2002, 261, 21-36.
61. Bonjardim, C.A.; Ferreira, P.C.P.; Kroon, E.G. Interferons: Signaling, antiviral and viral evasion. Immunol. Lett., 2009, 122, 1-11.
62. Meager, A. The interferons: past, present and future. Dig. LiverDis., 2009, 3, 3-8.
63. Dunn, G.P.; Koebel, C.M.; Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol., 2006, 6, 836-48.
64. Stark, G.R.; Kerr, I.M.; Williams, B.R.G.; Silverman, R.H.; Schreiber, R.D. How cells respond to interferons. Annu. Rev. Biochem., 1998, 67, 227-64.
65. Sadler, A.J.; Williams, B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol., 2008, 8, 559-68.
66. Jelkman, W.; Metzen, E. Erythropoietin in the control of red cellproduction. Ann. Anat., 1996, 178, 391-403.
67. Lappin, T. The cellular biology of erythropoietin receptors. Oncologist, 2003, 8, 15-8.
68. Ruifrok, W.P.T.; de Boer, R.A.; Westenbrink, B.D.; van Veldhuisen, D.J.; van Gilst W.H. Erythropoietin in cardiac disease: newfeatures of an old drug. Eur. J. Pharmacol., 2008, 585, 270-7.
69. Siren, A.L.; Ehrenreich, H. Erythropoietin -a novel concept forneuroprotection. Eur. Arch. Psychiatry Clin. Neurosci., 2001, 251, 179-84.
70. Moore E.; Bellomo, R. Erythropoietin (EPO) in acute kidney injury. Ann. Intensive Care, 2011, 1, 1-10.
71. Bahlmann, F.H.; Fliser, D. Erythropoietin and renoprotection. Curr. Opin. Nephrol. Hypertens., 2009, 18, 15-20.
72. Elliott, S.; Pham, E.; Macdougall, I.C. Erythropoietins: a commonmechanism of action. Exp. Hematol., 2008, 36, 1573-84.
73. Genc, S.; Koroglu, T.F.; Genc, K. Erythopoietin and the nervoussystem. Brain Res., 2004, 1000, 19-31.
74. Bartels, C.; Spate, K.; Krampe, H.; Ehrenreich, H. Recombinanthuman erythropoietin: novel strategies for neuroprotective/neuroregenerativetreatment of multiple sclerosis. Ther Adv. Neurol. Disord., 2008, 1, 193-206.
75. Hasselblatt, M.; Ehrenreich, H.; Siren, A.L. The brain erythropoietinsystem and its potential for therapeutic exploitation in braindisease. J. Neurosurg. Anesthesiol., 2006, 18, 132-8.
76. Tugyan, K.; Ozbal, S.; Cilaker, S.; Kiray, M.; Pekcetin, C.; Ergur, B.U.; Kumral, A. Neuroprotective effect of erythropoietin on nandrolonedecanoate- induced brain injury in rats. Neurosci. Lett., 2013, 533, 28-33.
77. Brines, M.L.; Ghezzi, P.; Keenan, S.; Agnello, D.; Lanrolle, N.C.; Cerami, C.; Itri, L.M.; Cerami, A. erythoropoietin crosses theblood-brain barrier to protect against experimental brain injury. PNAS, 2000, 97, 10526-31.
78. Bartesaghi, S.; Marinovich, M.; Corsini, E.; Galli, C.L.; Viviani, B. Erythropoietin: a novel neuroprotective cytokine. NeuroToxicology, 2005, 26, 923-8.
79. Raccah, D., Insulin therapy in patients with Type 2 diabetes mellitus:treatment to target fasting and postprandial blood glucose levels. Insulin, 2006, 1, 158-65.
80. Westphal, S.A.; Palumbo, P.J. Weight gain and management concernsin patients on insulin therapy. Insulin, 2006, 2, 31-6.
81. Ozgur, A.; Yurt Lambrecht, F.; Ocakoglu, A.; Gunduz, C.; Yucebas, M. Synthesis and biological evaluation of radiolabeled photosensitizerlinked bovine serum albumin nanoparticles as a tumorimaging agent. Int. J. Pharm., 2012, 422, 472-8.
82. Cho, K.; Wang, X.; Nie, S.; Chen, Z.G.; Shin, D.M. Therapeuticnanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14, 1310-6.
83. 99mTc-EDDA/ tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptorpositive tumor cell lines. J. Drug Target., DOI:10.3109/1061186X.2012.757772.